Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure
Nina Worel(Medical University of Vienna), Hildegard Greinix(Medical University of Graz), Reinhard Ruckser(Donauspital), Viktor Mayr(Universitätsklinikum Krems), Gerhard Kopetzky(Universitätsklinikum St. Pölten), G. Fritsch(Paracelsus Medical University), Karoline V. Gleixner(Medical University of Vienna), Peter Kalhs(Medical University of Vienna), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Georg Engelich(Fachhochschule Wiener Neustadt), Werner Rabitsch(Medical University of Vienna), Niklas Zojer(University of Vienna), Klaus Geißler(University of Vienna), Konrad Rosskopf(Medical University of Graz), Felix Keil(Hanusch Hospital), Alexandra Böhm(Krankenhaus der Elisabethinen), Claudia Zoghlami(Klinik Hietzing), Hermine Agis(Medical University of Vienna), Regina Reisner(Hanusch Hospital), Gerda Leitner(Medical University of Vienna)
Cited by 36
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
|Blood|2011|448
One million haemopoietic stem-cell transplants: a retrospective observational study
|The Lancet Haematology|2015|434